Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategy
RGEN logo

Repligen's Revenue Holds Steady at $634M Amid Filtration Surge and Proteins Dip

RGEN10-KFiling Date: 3/14/2025
Repligen Corporation
Description

What this story covers

Repligen's 2024 10-K shows $634M revenue up 0.3%, driven by 9.2% Filtration growth to $373M offsetting 28% Proteins decline. Acquisitions like Tantti bolster gene therapy tech; robust $757M cash supports R&D amid competition and supply risks.

Story snapshot

CompanyRepligen Corporation
TickerRGEN
VariantStandard detailed
Duration13:44
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0000950170-25-038999

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in